Cryosite Limited (ASX:CTE)

Australia · Delayed Price · Currency is AUD

1.150

+0.090 (8.49%)

Jun 25, 2026, 10:57 AM AEST

55.41% (1Y)

Market Cap	56.13M +58.6%
Revenue (ttm)	15.75M +22.6%
Net Income	2.18M +19.2%
EPS	0.04 +14.4%
Shares Out	48.81M
PE Ratio	26.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,150
Open	1.150
Previous Close	1.060
Day's Range	1.150 - 1.150
52-Week Range	0.660 - 1.300
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 10, 2026

About Cryosite

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell ... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1999

Employees 25

Stock Exchange Australian Securities Exchange

Ticker Symbol CTE

Full Company Profile

Financial Performance

In fiscal year 2025, Cryosite's revenue was 14.12 million, an increase of 11.93% compared to the previous year's 12.61 million. Earnings were 1.88 million, an increase of 2.39%.

Financial Statements